×
About 519 results

ALLMedicine™ Prurigo Nodularis Center

Research & Reviews  253 results

Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Ass...
https://doi.org/10.1001/jamadermatol.2020.3071
JAMA Dermatology; Kimel M, Zeidler C et. al.

Sep 16th, 2020 - There is an unmet need for psychometrically sound instruments to measure pruritus associated with prurigo nodularis (PN). To evaluate the psychometric properties of the itch numeric rating scale (itch NRS), both the Worst Itch Numeric Rating Scale...

Practical approaches for diagnosis and management of prurigo nodularis: US expert panel...
https://doi.org/10.1016/j.jaad.2020.07.025
Journal of the American Academy of Dermatology; Elmariah S, Kim B et. al.

Jul 18th, 2020 - Prurigo nodularis (PN) is a chronic disease characterized by intensely pruritic, raised, nodular lesions. As there are currently no US Food and Drug Administration-approved therapies specifically for PN, management is highly variable and no consen...

Emergency department utilization by patients with prurigo nodularis in the United States.
https://doi.org/10.1016/j.jaad.2020.06.1002
Journal of the American Academy of Dermatology; Whang KA, Gabriel S et. al.

Jun 30th, 2020 - Emergency department utilization by patients with prurigo nodularis in the United States.|2020|Whang KA,Gabriel S,Chavda R,Kwatra SG,|

Prurigo Nodularis: Epidemiology and Clinical Features.
https://doi.org/10.1016/j.jaad.2020.04.183
Journal of the American Academy of Dermatology; Huang AH, Williams KA et. al.

May 26th, 2020 - Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules that favor the extensor surfaces of the extremities and the trunk. In addition to its significant impact on quality of life, ...

Prurigo Nodularis: Pathogenesis and Management.
https://doi.org/10.1016/j.jaad.2020.04.182
Journal of the American Academy of Dermatology; Williams KA, Huang AH et. al.

May 23rd, 2020 - Prurigo nodularis (PN) is a chronic skin condition characterized by severely pruritic nodules that cause a profound negative impact on quality of life. In the second article of this 2-part continuing medical education series, we focus on reviewing...

see more →

Clinicaltrials.gov  253 results

Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Ass...
https://doi.org/10.1001/jamadermatol.2020.3071
JAMA Dermatology; Kimel M, Zeidler C et. al.

Sep 16th, 2020 - There is an unmet need for psychometrically sound instruments to measure pruritus associated with prurigo nodularis (PN). To evaluate the psychometric properties of the itch numeric rating scale (itch NRS), both the Worst Itch Numeric Rating Scale...

Practical approaches for diagnosis and management of prurigo nodularis: US expert panel...
https://doi.org/10.1016/j.jaad.2020.07.025
Journal of the American Academy of Dermatology; Elmariah S, Kim B et. al.

Jul 18th, 2020 - Prurigo nodularis (PN) is a chronic disease characterized by intensely pruritic, raised, nodular lesions. As there are currently no US Food and Drug Administration-approved therapies specifically for PN, management is highly variable and no consen...

Emergency department utilization by patients with prurigo nodularis in the United States.
https://doi.org/10.1016/j.jaad.2020.06.1002
Journal of the American Academy of Dermatology; Whang KA, Gabriel S et. al.

Jun 30th, 2020 - Emergency department utilization by patients with prurigo nodularis in the United States.|2020|Whang KA,Gabriel S,Chavda R,Kwatra SG,|

Prurigo Nodularis: Epidemiology and Clinical Features.
https://doi.org/10.1016/j.jaad.2020.04.183
Journal of the American Academy of Dermatology; Huang AH, Williams KA et. al.

May 26th, 2020 - Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules that favor the extensor surfaces of the extremities and the trunk. In addition to its significant impact on quality of life, ...

Prurigo Nodularis: Pathogenesis and Management.
https://doi.org/10.1016/j.jaad.2020.04.182
Journal of the American Academy of Dermatology; Williams KA, Huang AH et. al.

May 23rd, 2020 - Prurigo nodularis (PN) is a chronic skin condition characterized by severely pruritic nodules that cause a profound negative impact on quality of life. In the second article of this 2-part continuing medical education series, we focus on reviewing...

see more →

News  13 results

Nemolizumab tames itching in prurigo nodularis patients in phase 2 study
https://www.mdedge.com/dermatology/article/217918/medical-dermatology/nemolizumab-tames-itching-prurigo-nodularis-patients?channel=39212
Heidi Splete

Feb 26th, 2020 - Adults with moderate to severe prurigo nodularis who were treated with the investigational drug nemolizumab showed significant improvement in itching, compared with patients treated with placebo, according to data from a phase 2 trial of 70 patien.

Rapid improvement seen with nemolizumab for prurigo nodularis in phase 2b study
https://www.mdedge.com/dermatology/article/211733/medical-dermatology/rapid-improvement-seen-nemolizumab-prurigo-nodularis?channel=39313
Bruce Jancin

Nov 6th, 2019 - MADRID – Nemolizumab, an investigational humanized monoclonal antibody targeting the interleukin-31 receptor alpha subunit, achieved rapid and clinically meaningful improvement in both itch and skin lesions of severe prurigo nodularis in a phase 2.

Serlopitant quells prurigo nodularis in phase 2 study
https://www.mdedge.com/dermatology/article/178171/medical-dermatology/serlopitant-quells-prurigo-nodularis-phase-2-study
Bruce Jancin

Oct 26th, 2018 - PARIS – The investigational oral neurokinin-1 receptor antagonist serlopitant significantly reduced multiple distressing sensory symptoms of prurigo nodularis in a 127-patient, randomized, placebo-controlled trial, Sonja Stander, MD, said at the a.

Review finds some therapies show promise in managing prurigo nodularis
https://www.mdedge.com/dermatology/article/176946/medical-dermatology/review-finds-some-therapies-show-promise-managing
Jill D. Pivovarov

Oct 10th, 2018 - FROM THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Recent success in the use of neurokinin-1 receptor antagonists, k-opioid receptor modulators, and interleukin (IL)-31 receptor antibodies for treatment of prurigo nodularis (PN) suggests that.

Serlopitant is itching to quell chronic pruritus
https://www.mdedge.com/familymedicine/article/152253/medical-dermatology/serlopitant-itching-quell-chronic-pruritus
Dermatology News; Bruce Jancin

Nov 16th, 2017 - GENEVA – Serlopitant, a novel once-daily oral neurokinin-1 receptor antagonist, brought significant improvement for patients with treatment-resistant chronic pruritus as early as day 2, in a phase 2 randomized trial, Paul Kwon, MD, reported at the.

see more →